Cargando…
A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy
Tisagenlecleucel is associated with remarkable outcomes in treating patients up to the age of 25 years with refractory B-cell acute lymphoblastic leukemia (ALL). Yet, due to unique and potentially life-threatening complications, access remains limited to higher-resource and certified centers. Report...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638171/ https://www.ncbi.nlm.nih.gov/pubmed/36353531 http://dx.doi.org/10.3389/fonc.2022.1022901 |
_version_ | 1784825353122873344 |
---|---|
author | Ragoonanan, Dristhi Bhar, Saleh Mohan, Gopi Beltramo, Fernando Khazal, Sajad J. Hurley, Caitlin Andersen, Clark Margossian, Steven Neelapu, Sattva S. Shpall, Elizabeth Gutierrez, Cristina Tewari, Priti Shoberu, Basirat Talleur, Aimee McCall, David Nunez, Cesar Cuglievan, Branko Tambaro, Francesco Paolo Petropoulos, Demetrios Abdel-Azim, Hisham Mahadeo, Kris M. |
author_facet | Ragoonanan, Dristhi Bhar, Saleh Mohan, Gopi Beltramo, Fernando Khazal, Sajad J. Hurley, Caitlin Andersen, Clark Margossian, Steven Neelapu, Sattva S. Shpall, Elizabeth Gutierrez, Cristina Tewari, Priti Shoberu, Basirat Talleur, Aimee McCall, David Nunez, Cesar Cuglievan, Branko Tambaro, Francesco Paolo Petropoulos, Demetrios Abdel-Azim, Hisham Mahadeo, Kris M. |
author_sort | Ragoonanan, Dristhi |
collection | PubMed |
description | Tisagenlecleucel is associated with remarkable outcomes in treating patients up to the age of 25 years with refractory B-cell acute lymphoblastic leukemia (ALL). Yet, due to unique and potentially life-threatening complications, access remains limited to higher-resource and certified centers. Reports of inequity and related disparities in care are emerging. In this multicenter study of ALL patients admitted for anti-leukemia therapy, who required pediatric intensive care (ICU) support (n = 205), patients receiving tisagenlecleucel (n = 39) were compared to those receiving conventional chemotherapy (n = 166). The median time to ICU transfer was 6 (0–43) versus 1 (0–116) days, respectively (p < 0.0001). There was no difference in the use of vasopressor, ionotropic, sedating, and/or paralytic agents between groups, but use of dexamethasone was higher among tisagenlecleucel patients. Patients receiving tisagenlecleucel were more likely to have cardiorespiratory toxicity (p = 0.0002), but there were no differences in diagnostic interventions between both groups and/or differences in ICU length of stay and/or overall hospital survival. Toxicities associated with tisagenlecleucel are generally reversible, and our findings suggest that resource utilization once admitted to the ICU may be similar among patients with ALL receiving tisagenlecleucel versus conventional chemotherapy. As centers consider improved access to care and the feasibility of tisagenlecleucel certification, our study may inform strategic planning. |
format | Online Article Text |
id | pubmed-9638171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96381712022-11-08 A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy Ragoonanan, Dristhi Bhar, Saleh Mohan, Gopi Beltramo, Fernando Khazal, Sajad J. Hurley, Caitlin Andersen, Clark Margossian, Steven Neelapu, Sattva S. Shpall, Elizabeth Gutierrez, Cristina Tewari, Priti Shoberu, Basirat Talleur, Aimee McCall, David Nunez, Cesar Cuglievan, Branko Tambaro, Francesco Paolo Petropoulos, Demetrios Abdel-Azim, Hisham Mahadeo, Kris M. Front Oncol Oncology Tisagenlecleucel is associated with remarkable outcomes in treating patients up to the age of 25 years with refractory B-cell acute lymphoblastic leukemia (ALL). Yet, due to unique and potentially life-threatening complications, access remains limited to higher-resource and certified centers. Reports of inequity and related disparities in care are emerging. In this multicenter study of ALL patients admitted for anti-leukemia therapy, who required pediatric intensive care (ICU) support (n = 205), patients receiving tisagenlecleucel (n = 39) were compared to those receiving conventional chemotherapy (n = 166). The median time to ICU transfer was 6 (0–43) versus 1 (0–116) days, respectively (p < 0.0001). There was no difference in the use of vasopressor, ionotropic, sedating, and/or paralytic agents between groups, but use of dexamethasone was higher among tisagenlecleucel patients. Patients receiving tisagenlecleucel were more likely to have cardiorespiratory toxicity (p = 0.0002), but there were no differences in diagnostic interventions between both groups and/or differences in ICU length of stay and/or overall hospital survival. Toxicities associated with tisagenlecleucel are generally reversible, and our findings suggest that resource utilization once admitted to the ICU may be similar among patients with ALL receiving tisagenlecleucel versus conventional chemotherapy. As centers consider improved access to care and the feasibility of tisagenlecleucel certification, our study may inform strategic planning. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638171/ /pubmed/36353531 http://dx.doi.org/10.3389/fonc.2022.1022901 Text en Copyright © 2022 Ragoonanan, Bhar, Mohan, Beltramo, Khazal, Hurley, Andersen, Margossian, Neelapu, Shpall, Gutierrez, Tewari, Shoberu, Talleur, McCall, Nunez, Cuglievan, Tambaro, Petropoulos, Abdel-Azim and Mahadeo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ragoonanan, Dristhi Bhar, Saleh Mohan, Gopi Beltramo, Fernando Khazal, Sajad J. Hurley, Caitlin Andersen, Clark Margossian, Steven Neelapu, Sattva S. Shpall, Elizabeth Gutierrez, Cristina Tewari, Priti Shoberu, Basirat Talleur, Aimee McCall, David Nunez, Cesar Cuglievan, Branko Tambaro, Francesco Paolo Petropoulos, Demetrios Abdel-Azim, Hisham Mahadeo, Kris M. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy |
title | A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy |
title_full | A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy |
title_fullStr | A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy |
title_full_unstemmed | A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy |
title_short | A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy |
title_sort | multicenter study of icu resource utilization in pediatric, adolescent and young adult patients post car-t therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638171/ https://www.ncbi.nlm.nih.gov/pubmed/36353531 http://dx.doi.org/10.3389/fonc.2022.1022901 |
work_keys_str_mv | AT ragoonanandristhi amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT bharsaleh amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT mohangopi amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT beltramofernando amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT khazalsajadj amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT hurleycaitlin amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT andersenclark amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT margossiansteven amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT neelapusattvas amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT shpallelizabeth amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT gutierrezcristina amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT tewaripriti amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT shoberubasirat amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT talleuraimee amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT mccalldavid amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT nunezcesar amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT cuglievanbranko amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT tambarofrancescopaolo amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT petropoulosdemetrios amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT abdelazimhisham amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT mahadeokrism amulticenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT ragoonanandristhi multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT bharsaleh multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT mohangopi multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT beltramofernando multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT khazalsajadj multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT hurleycaitlin multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT andersenclark multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT margossiansteven multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT neelapusattvas multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT shpallelizabeth multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT gutierrezcristina multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT tewaripriti multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT shoberubasirat multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT talleuraimee multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT mccalldavid multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT nunezcesar multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT cuglievanbranko multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT tambarofrancescopaolo multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT petropoulosdemetrios multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT abdelazimhisham multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy AT mahadeokrism multicenterstudyoficuresourceutilizationinpediatricadolescentandyoungadultpatientspostcarttherapy |